Cannanda CB2 Hemp Seed Oil 240ml

The Legal, Non-Prescription Alternative

Cannanda is proud and excited to present one of our greatest innovations: our CB2™ blend is a legal, non-prescription alternative to cannabidiol (CBD) or used to enhance your CBD experience. CBD is the popular cannabis compound that has significant health benefits, but lacks the psychoactive effects of its sister compound, THC. This means you get a number of incredible health benefits without feeling "high," and it delivers these benefits by positively influencing the endocannabinoid system (ECS; the body's master regulator of homeostasis).

Unfortunately, in Canada, CBD continues to be legally available by prescription only, or not-so-legally through cannabis dispensaries. After legalization later in 2018, CBD will continue to be available only through controlled distribution from licensed outlets only.

In order to bring these health benefits to a growing number of individuals through open distribution, Cannanda's research and development has created our proprietary CB2™ terpene blend, which harnesses the power of terpenes in a very specific blend that promotes the health of the ECS. This unique blend achieves its health-giving benefits through the activation of one of the main receptors of the ECS, a receptor called the cannabinoid receptor type 2 (CB2).

However, if you're already CBD user, the benefits could be even greater! There is a perfect synergy between Cannanda's CB2 and CBD products (read more below).

Activating the CB2 Receptor

CB2 is one of the two main receptors of the ECS. There are numerous benefits to activating this receptor without activating the CB1 receptor (the receptor THC activates, and is responsible for the "high" associated with cannabis). The following is a small list of studies illustrating the benefits of CB2 activation.

Pain & Inflammation:

• The CB2 receptor and its role as a regulator of inflammation (Cell Mol Life Sci. 2016; 73(23): 4449-70.)
• Targeting CB2 receptors and the endocannabinoid system for the treatment of pain (Brain Res Rev. 2009 Apr; 60(1): 255-266.)
• Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain (Br J Pharmacol. 2008 Jan; 153(2): 319–334.)

Autism Spectrum Disorders:

• Endocannabinoid signalling in autism (Neurotherapeutics. 2015 Oct; 12(4): 837–847.)
• Endocannabinoid signal dysregulation in autism spectrum disorders (int J Mol Sci. 2017; 18: 1425.)

Degenerative neurological conditions:

• CB2 cannabinoid receptor as potential target against Alzheimer’s Disease (Front Neurosci. 2016; 10: 243.)
• Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders (Front Neurosci. 2016; 10: 406.)
• Central CB2 receptors in inflammation-driven neurodegeneration: dysregulation and therapeutic potential (Neural Regen Res. 2016 Sep; 11(9): 1409–1410.)
• Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson’s Disease (Front Neurosci. 2016; 10: 321.)
• CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson’s disease (Exp Mol Med. 2016 Jan; 48(1): e205.)
• CB2 receptor: Potential role in immunomodulation and neuroinflammation (J Neuroimmune Pharmacol. 2013 Jun; 8(3): 608-620.)
• CB2 receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies (Br J Pharmacol. 2008 Jan; 153(2): 216–225.)
• Cannabinoid CB2 receptors in human brain inflammation (Br J Pharmacol. 2008 Jan; 153(2): 277–285.)

Osteoarthritis:

• Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint (PLoS One. 2013; 8(11): e80440.)
• Expression of cannabinoid receptors in human osteoarthritic cartilage: Implications for future therapies (Cannabis Cannabinoid Res. 2016 Jan 1;1(1):3-15)

Rheumatoid arthritis:

• CB2 as a potential therapeutic target in rheumatoid arthritis (Musculoskeletal Disorders. 2014; 15: 275.)

Immune system modulation:

• CB2: Potential role in immunomodulation and neuroinflammation (J Neuroimmune Pharmacol. 2013 Jun; 8(3): 608-620.)
• Emerging role of the CB2 cannabinoid receptor in immune regulation and therapeutic prospects (Expert Rev Mol Med. 2009 Jan 20; 11: e3.)

Cardiovascular:

• CB2 drives neurogenesis and improves functional outcome after stroke (Stroke. 2017 Jan;(48)1:204-212.)
• Prospects for creation of cardioprotective drugs based on cannabinoid receptor agonists (J Cardiovasc Pharmacol Ther. 2016 May;21(3):262-72.)
• CB2 in atherosclerosis and acute cardiovascular diseases (Curr Med Chem. 2014;(21)35:4046-58.)

Migraine:

• Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model (J Headache Pain. 2014; 15(1): 14.)